FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W2023778178> ?p ?o ?g. }

• W2023778178 endingPage "82A" @default.
• W2023778178 startingPage "72A" @default.
• W2023778178 abstract "Patients with supraventricular arrhythmias have been safely and effectively treated with flecainide. We conducted an open-label, 20-center trial to define further the safety and efficacy profile of oral flecainide in patients with supraventricular arrhythmias, including atrial tachycardias (ectopic or multifocal), atrial-ventricular tachycardias (reentrant), paroxysmal atrial fibrillation/flutter (PAF), and chronic atrial fibrillation (CAF). Our study population of 151 patients with documented supraventricular arrhythmias requiring treatment included 67 with paroxysmal supraventricular tachycardia (PSVT), 67 with PAF (symptoms <15 days), and 17 with CAP (symptoms >15 days). The initial flecainide dose of 100 mg twice daily could be increased by 50 mg bid every 4 days to a maximum of 200 mg twice daily. Patients who were effectively treated could receive flecainide for 1 year. The study was terminated April 26, 1989, in response to interim results reported by the Cardiac Arrhythmia Suppression Trial (CAST). All patients were removed from the study by August 1989. At study termination 87% of PSVT, 73% of PAF, and 56% of CAP patients had improved symptomatically while on flecainide therapy. Eleven patients experienced cardiac adverse experiences: proarrhythmic events (3 patients), new or worsened congestive heart failure (7 patients), sinus pauses (1 patient). Cardiac side effects appeared to be more frequent in patients in the CAF group (5/17 patients), all of whom had structural heart disease. Overall, 45 (67%) PSVT, 43 (64%) PAF, and 9 (56%) CAP patients reported at least 1 noncardiac adverse experience; the most common were abnormal vision, dizziness, and headaches. One patient from the CAF group died; the death was considered to be unrelated to flecainide. Flecainide appears to be safe and effective treatment for patients with supraventricular arrhythmias of a variety of mechanisms and appears particularly effective for patients with PSVT. The efficacy is lowest and side effects most frequent in patients with CAF, as seen with other trials of antiarrhythmic medication in these patients. In the context of the CAST experience and other trials of antiarrhythmic drugs in patients with CAF, the balance of risk and benefit of therapy should be considered carefully before initiating treatment." @default.
• W2023778178 created "2016-06-24" @default.
• W2023778178 creator A5003936991 @default.
• W2023778178 creator A5040656972 @default.
• W2023778178 creator A5042957633 @default.
• W2023778178 creator A5052078081 @default.
• W2023778178 creator A5065789483 @default.
• W2023778178 creator A5079800282 @default.
• W2023778178 date "1996-01-01" @default.
• W2023778178 modified "2023-10-03" @default.
• W2023778178 title "Safety and utility of flecainide acetate in the routine care of patients with supraventricular tachyarrhythmias: Results of a mmulticenter trial" @default.
• W2023778178 cites W1841210729 @default.
• W2023778178 cites W1952117966 @default.
• W2023778178 cites W1964718370 @default.
• W2023778178 cites W1967775446 @default.
• W2023778178 cites W1969234821 @default.
• W2023778178 cites W1972129938 @default.
• W2023778178 cites W1974475977 @default.
• W2023778178 cites W1974984582 @default.
• W2023778178 cites W1979453398 @default.
• W2023778178 cites W1980069880 @default.
• W2023778178 cites W1980277885 @default.
• W2023778178 cites W1987576284 @default.
• W2023778178 cites W1987773120 @default.
• W2023778178 cites W1987936575 @default.
• W2023778178 cites W1989019770 @default.
• W2023778178 cites W1999651496 @default.
• W2023778178 cites W2006116430 @default.
• W2023778178 cites W2008796765 @default.
• W2023778178 cites W2014707446 @default.
• W2023778178 cites W2021283980 @default.
• W2023778178 cites W2023545148 @default.
• W2023778178 cites W2051199416 @default.
• W2023778178 cites W2062125806 @default.
• W2023778178 cites W2064074785 @default.
• W2023778178 cites W2066235081 @default.
• W2023778178 cites W2069674325 @default.
• W2023778178 cites W2071412839 @default.
• W2023778178 cites W2074502478 @default.
• W2023778178 cites W2074913627 @default.
• W2023778178 cites W2076534662 @default.
• W2023778178 cites W2089951092 @default.
• W2023778178 cites W2096746249 @default.
• W2023778178 cites W2097585738 @default.
• W2023778178 cites W2107115979 @default.
• W2023778178 cites W2113663588 @default.
• W2023778178 cites W2116017164 @default.
• W2023778178 cites W2141022806 @default.
• W2023778178 cites W2141633106 @default.
• W2023778178 cites W2149972765 @default.
• W2023778178 cites W2158454946 @default.
• W2023778178 cites W2170140167 @default.
• W2023778178 cites W2280529022 @default.
• W2023778178 cites W2286484588 @default.
• W2023778178 cites W2324628668 @default.
• W2023778178 cites W2614168425 @default.
• W2023778178 doi "https://doi.org/10.1016/s0002-9149(97)89121-7" @default.
• W2023778178 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/8607395" @default.
• W2023778178 hasPublicationYear "1996" @default.
• W2023778178 type Work @default.
• W2023778178 sameAs 2023778178 @default.
• W2023778178 citedByCount "46" @default.
• W2023778178 countsByYear W20237781782012 @default.
• W2023778178 countsByYear W20237781782013 @default.
• W2023778178 countsByYear W20237781782014 @default.
• W2023778178 countsByYear W20237781782015 @default.
• W2023778178 countsByYear W20237781782016 @default.
• W2023778178 countsByYear W20237781782018 @default.
• W2023778178 countsByYear W20237781782019 @default.
• W2023778178 countsByYear W20237781782021 @default.
• W2023778178 crossrefType "journal-article" @default.
• W2023778178 hasAuthorship W2023778178A5003936991 @default.
• W2023778178 hasAuthorship W2023778178A5040656972 @default.
• W2023778178 hasAuthorship W2023778178A5042957633 @default.
• W2023778178 hasAuthorship W2023778178A5052078081 @default.
• W2023778178 hasAuthorship W2023778178A5065789483 @default.
• W2023778178 hasAuthorship W2023778178A5079800282 @default.
• W2023778178 hasConcept C126322002 @default.
• W2023778178 hasConcept C164705383 @default.
• W2023778178 hasConcept C197934379 @default.
• W2023778178 hasConcept C2776639339 @default.
• W2023778178 hasConcept C2776934708 @default.
• W2023778178 hasConcept C2777008848 @default.
• W2023778178 hasConcept C2778292772 @default.
• W2023778178 hasConcept C2779161974 @default.
• W2023778178 hasConcept C2779837460 @default.
• W2023778178 hasConcept C2780074459 @default.
• W2023778178 hasConcept C2780283014 @default.
• W2023778178 hasConcept C2910597771 @default.
• W2023778178 hasConcept C42219234 @default.
• W2023778178 hasConcept C71924100 @default.
• W2023778178 hasConceptScore W2023778178C126322002 @default.
• W2023778178 hasConceptScore W2023778178C164705383 @default.
• W2023778178 hasConceptScore W2023778178C197934379 @default.
• W2023778178 hasConceptScore W2023778178C2776639339 @default.
• W2023778178 hasConceptScore W2023778178C2776934708 @default.
• W2023778178 hasConceptScore W2023778178C2777008848 @default.
• W2023778178 hasConceptScore W2023778178C2778292772 @default.

• next